Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar® in Postmenopausal Osteoporotic Women: A Randomized Double-Blind Clinical Trial



Tabatabaeimalazy O1, 2 ; Norani M3 ; Heshmat R4 ; Qorbani M5 ; Vosoogh A2 ; Afrashteh B2 ; Kahkeshan F6 ; Ajami A6 ; Larijani B2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran
  6. 6. Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Public Health Published:2018

Abstract

Background: Due to high cost and burden of osteoporosis, it is reasonable to focus on the reduction of fractures as the main goal of treatment. We compared the efficacy and safety of a new biosimilar recombinant human parathyroid hormone (CinnoPar®, CinnaGen, Iran) to the reference product (Forteo®, Eli Lilly, USA) in a randomized double-blind clinical trial (RCT). Methods: Overall, 104 osteoporotic postmenopausal women aged 45-75 yr were randomized to receive 20 µg daily subcutaneous injections of either Forteo® or CinnoPar® for 6-months from 2011-2012. Bone biomarkers were measured at baseline, and during first, third, and sixth month's follow-up along with lumbar spine, total hip, and femoral neck bone mineral density (BMD) assessment at the baseline and six months after that. The study was registered in Iranian registry of clinical trials under the registration number of IRCT138810121414N5. The endpoints were to compare bone biomarkers, BMD and drug safety between groups. Data analysis was performed using SPSS 11. Results: Age range of ninety-four patients who completed the study was 42-81 yr. Participants were divided into Forteo (45 subjects) and CinnoPar (49 subjects) groups. No significant difference in terms of bone biomarkers or BMD scores was shown between groups (P≥0.05). The most prevalent side effects were hypercalcemia and hypercalciuria without any significant statistical differences between groups. Conclusion: CinnoPar® can be considered as a good alternative therapy for Forteo® in postmenopausal osteoporotic women due to its comparable efficacy and safety properties. © 2018, Iranian Journal of Public Health. All rights reserved.
Related Docs
1. New Horizons in Treatment of Osteoporosis, DARU# Journal of Pharmaceutical Sciences (2017)
2. Impact of Medicinal Plants on Bone Health; a Systematic Review and Meta-Analysis of Clinical Studies, Journal of Agriculture and Food Research (2025)
3. Navigating Ethical Dilemmas in Complementary and Alternative Medicine: A Narrative Review, Journal of Medical Ethics and History of Medicine (2024)
Experts (# of related papers)
View all Related Experts
Ozra Tabatabaei-Malazy (3)
Bagher Larijani (3)